Artemisinin is a drug used to treat multi-drug resistant strains of falciparum malaria. The compound (a sesquiterpene lactone) is isolated from the plant Artemisia annua. Not all plants of this species contain artemisinin.
When a mosquito begins to nibble on you, it is not merely feeding on your blood, it is also injecting its saliva into your skin. If that saliva happens to be full of parasites carrying malaria or other diseases from its last victim, then most likely you will become infected, too.
News-Medical interviews Sir Brian Greenwood about raising awareness for malaria during the COVID-19 pandemic and achieving elimination of the disease.
Much of common pharmaceutical development today is the product of laborious cycles of tweaking and optimization.
New data provide the first clinical evidence that drug-resistant mutations in the malaria parasite Plasmodium falciparum may be gaining a foothold in Africa.
Caused by SARS-CoV-2, the ongoing COVID-19 pandemic has led to over 121.2 million cases and over 2.6 million deaths worldwide. An interesting new study examines the potential antiviral activity of compounds present in the plant Artemisia annua L.
Bay Area Lyme Foundation, a leading sponsor of Lyme disease research in the U.S., today announced the publication of new data finding that five herbal medicines had potent activity compared to commonly-used antibiotics in test tubes against Babesia duncani, a malaria-like parasite found on the West Coast of the U.S. that causes the disease babesiosis.
A team of scientists from Germany and the USA recently explored the effectiveness of traditional plant medicines in treating SARS-CoV-2 infection.
Researchers in the United States have shown that extracts of an aromatic herb called Artemisia annua inhibit the replication of severe acute respiratory coronavirus (SARS-CoV-2) – the agent responsible for the current coronavirus disease 2019 (COVID-19) pandemic.
Exposure to suboptimal doses of the antiparasitic drug artemisinin could increase the sexual conversion rate of the malaria parasite Plasmodium falciparum, thereby increasing the probability of transmission, according to a study led by the Barcelona Institute for Global Health (ISGlobal), an institution supported by "la Caixa" Foundation.
New insight on the molecular mechanisms that allow malaria parasites to move and spread disease within their hosts has been published today in the open-access eLife journal.
In a recent, methodologically robust bioRXiv preprint paper, researchers from Germany, Denmark and Hong Kong report in vitro efficacy of extracts from the sweet wormwood plant (Artemisia annua), but also artemisinin, artesunate and artemether derivatives against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Even when a person suffering from malaria is burning up with fever and too sick to function, the tiny blood-eating parasites lurking inside them continue to flourish, relentlessly growing and multiplying as they gobble up the host's red blood cells.
News-Medical spoke to researchers from the University of Warwick about their research investigating natural antimicrobials and their potential as antibiotics.
Resistance to artemisinin, the main component of the current antimalarial treatments recommended by WHO, is already widespread in South-East Asia, but it had not previously been described in Africa.
Southwest Research Institute and The Uni-versity of Texas at San Antonio are working to synthesize novel highly potent derivatives of the antimalarial drug artemisinin with the goal of creating a powerful, cost-effective malaria treatment.
The first study to elucidate the dynamics of membrane cholesterol transport in erythrocytes has been successfully concluded using holotomography microscopy.
A paper recently published in Nature Communications is the first to show a connection between demand from certain developed countries for agricultural commodities and the growing risk of malaria in the countries that supply those goods.
The U.S. Army Medical Research and Development Command announced today that the U.S. Food and Drug Administration granted marketing approval for Artesunate for Injection, an initial treatment for severe malaria.
A fast-acting anti-malarial compound discovered at St. Jude Children's Research Hospital was well tolerated and showed promising anti-malarial effects in the first study in humans.
A new study describing the outcome of a clinical trial of two malaria treatment protocols involving the use of triple therapies based on artemisinin reports their high efficacy and low adverse effects.